The 2025 Nobel Prize in Physiology or Medicine was awarded to Mary Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their groundbreaking work on autoimmune regulation. They identified the role of regulatory T-cells (Tregs) and the transcription factor FOXP3. Sakaguchi discovered Tregs in 1995, while Brunkow and Ramsdell identified the FOXP3 gene. Mutations in FOXP3 lead to IPEX, a lethal autoimmune disorder. Their research transformed the understanding of the immune system from a simple on/off switch to a dynamic ecosystem of activation and restraint, opening doors for new treatments for cancer and autoimmune diseases.
- The laureates identified regulatory T-cells (Tregs) which prevent the immune system from attacking the body's own cells.
- The FOXP3 gene was identified as the master regulator for the development and function of Tregs.
- This discovery has significant implications for treating autoimmune diseases, cancer, and improving organ transplant success.
The Union Health Ministry is pushing for strict drug compliance following reports of contaminated cough syrups. The Tamil Nadu Drugs Control Department found diethylene glycol (DEG) and ethylene glycol in samples of Coldrif, a cough syrup linked to child deaths in Rajasthan and Madhya Pradesh. These substances are nephrotoxic and highly dangerous. The Central Drugs Standard Control Organisation (CDSCO) has recommended cancelling the firm's manufacturing license. The article emphasizes the need for a zero-tolerance policy, hawk-like monitoring, and regular surprise inspections to uphold the 'Make in India' brand and protect public health from substandard pharmaceutical products.
- Contaminated cough syrups containing DEG and ethylene glycol have been linked to multiple child deaths in India.
- The CDSCO has recommended the cancellation of manufacturing licenses for firms failing to meet quality standards.
- Revised Schedule M norms are being implemented to ensure Indian pharmaceutical products meet global Good Manufacturing Practices (GMP).
The Union Health Ministry has directed drug manufacturers to strictly comply with the revised Schedule M norms under the Drugs and Cosmetics Act, 1940. This move follows reports of toxic cough syrups causing child deaths in Madhya Pradesh and Rajasthan. The revised norms mandate enhanced quality systems, including Pharmaceutical Quality Systems (PQS) and Quality Risk Management (QRM). Non-compliant units face license cancellation. The goal is to align Indian manufacturing standards with international Good Manufacturing Practices (GMP) to ensure product safety, prevent contamination like diethylene glycol (DEG), and maintain the global reputation of Indian pharmaceuticals.
- Schedule M of the Drugs and Cosmetics Act, 1940, prescribes the Good Manufacturing Practices (GMP) for pharmaceutical products in India.
- The revision introduces computerized storage systems and equipment validation to prevent contamination.
- Recent investigations found high levels of diethylene glycol (DEG) in 'Coldrif' cough syrup, leading to immediate production stops.
India faces a significant but underestimated burden of influenza, with two distinct seasonal peaks: winter (January-March) and post-monsoon (July-September). Current influenza vaccines provide short-lived protection, with antibody levels declining significantly within three to six months. Because the virus undergoes constant antigenic drift, experts suggest that a single annual shot is insufficient for year-round protection in India's tropical climate. The article advocates for a biannual vaccination schedule (June and November) and the inclusion of influenza vaccines in the Universal Immunisation Programme (UIP) to reduce hospitalisations and deaths, particularly among children and the elderly who are most at risk.
- India experiences two influenza peaks, unlike temperate countries which typically have one winter peak.
- Vaccine effectiveness drops significantly within 90 days, leaving populations vulnerable during the second annual peak.
- Less than 5% of Indians currently receive influenza vaccines due to a lack of government policy and public awareness.
The Union Health Ministry has launched risk-based inspections of 19 drug manufacturing units after the Tamil Nadu Drugs Control Department found diethylene glycol (DEG) above permissible limits in 'Coldrif' cough syrup. Produced by Sresan Pharmaceuticals in Kancheepuram, the syrup is linked to at least 10 child deaths in Madhya Pradesh and Rajasthan. While the Central Drugs Standard Control Organisation (CDSCO) initially found some samples free of DEG, state authorities in MP and Kerala have prohibited its sale. DEG and ethylene glycol are toxic industrial solvents sometimes used as cheap, illegal substitutes for pharmaceutical-grade glycerine, leading to severe health risks including renal failure.
- The Tamil Nadu Drugs Control Department identified a batch of Coldrif as 'not of standard quality' due to DEG adulteration.
- Diethylene glycol (DEG) is a poisonous substance that can cause renal failure and death, especially in children.
- The Union Health Ministry is conducting risk-based inspections across six states to identify quality failures in pharma units.
A conflict has emerged between Central and State health authorities regarding cough syrup safety. The Union Health Ministry stated that samples linked to child deaths in Madhya Pradesh and Rajasthan did not contain Diethylene Glycol (DEG) or Ethylene Glycol (EG). Conversely, Tamil Nadu's Drugs Control Department ordered a production halt for 'Coldrif' syrup after tests detected DEG adulteration. The Centre attributed some deaths to other causes like leptospirosis or improper home administration. An advisory has been issued cautioning against prescribing cough syrups to children under two years old and emphasizing the need for medical supervision.
- The Union Health Ministry claims samples tested by the NIV and CDSCO did not show toxic contaminants like DEG or EG.
- Tamil Nadu's Government Drugs Testing Laboratory found a batch of Coldrif syrup to be 'not of standard quality' due to DEG presence.
- Health authorities have issued a show-cause notice to Sresan Pharmaceutical, the manufacturer of the suspected Coldrif batch.
India is the third-largest e-waste generator globally, producing 2.2 million tonnes in 2025. A majority of this is processed in the informal sector using crude methods like acid baths and open-air burning. This releases toxic substances like lead, cadmium, and mercury, causing severe health issues including respiratory diseases, neurological damage, and DNA damage. Children in recycling clusters are particularly vulnerable, showing high levels of lead in their blood. While the E-Waste (Management) Rules, 2022, introduced Extended Producer Responsibility (EPR), implementation remains weak, and the informal sector still handles 95% of the waste.
- India generates 2.2 million tonnes of e-waste annually, with only 43% officially processed as of 2023-24.
- Informal recycling releases persistent organic pollutants (POPs) and heavy metals into the environment.
- E-waste exposure is linked to reduced IQ, behavioral disorders, and respiratory ailments, especially in children.
Marking 50 years of the Integrated Child Development Services (ICDS) scheme, Congress leader Jairam Ramesh stated that while the scheme has been renamed and subsumed under 'Mission Saksham Anganwadi and POSHAN 2.0,' its governance has not kept pace. He highlighted recommendations from a Parliamentary Standing Committee, including the need to double the wages of anganwadi workers and helpers. The Congress had suggested hiring additional workers for early childhood care. Ramesh also flagged the failure to revise cost norms for anganwadi services, which was supposed to happen in the 2020-21 financial year.
- ICDS is one of the world's largest child welfare programs, now part of Mission Saksham Anganwadi and POSHAN 2.0.
- Governance issues include stagnant wages for anganwadi workers and outdated cost norms for services.
- The scheme is critical for improving India's human development indicators, particularly child nutrition and health.
The article highlights the plight of Anshakalin Stri Parichars (ASPs) in Maharashtra and Accredited Social Health Activists (ASHAs) nationwide. Despite being the backbone of rural healthcare, delivering maternal care and immunizations, they are often classified as 'volunteers' rather than employees. This classification denies them minimum wages, job security, and social benefits. Their monthly wages have stagnated for years, often falling below subsistence levels. The neglect reveals a gendered and caste-inflected hierarchy in public health where skilled work by rural women is devalued. Protests across states demand fixed honoraria and recognition as government staff to secure rural health rights.
- ASPs and ASHAs are essential for rural health but lack formal worker status, leading to exploitation and low wages.
- The 'volunteer' label is used by states to justify underpaid labor and the absence of social security benefits like pensions.
- Rural women health workers face significant occupational risks, including snakebites and accidents, without insurance or compensation.
U.S. President Donald Trump has announced 100% tariffs on branded and patented medicines, effective October 1, to weaponize access to healthcare. While a 15% cap exists for the EU and Japan, hubs like the U.K., Switzerland, and Singapore face the full burden. India’s generics industry is currently spared, but uncertainty remains over Active Pharmaceutical Ingredients (APIs) and future expansions to biosimilars. This move could significantly raise drug costs for American patients and disrupt global supply chains, forcing nations like India to diversify export markets and accelerate alternative trade alliances to maintain pharma sector growth.
- The U.S. is imposing 100% tariffs on imported branded and patented medicines to reshape global supply chains.
- India's generics industry, which accounts for 90% of U.S. prescriptions, is currently exempt but remains vulnerable to future tariff expansions.
- There is significant uncertainty regarding whether Active Pharmaceutical Ingredients (APIs), dominated by India and China, will be included in the tariff net.
As global temperatures rise, access to cooling is shifting from a luxury to a public health necessity and a frontline adaptation need. In India, only about 5% of households own an air conditioner, mostly concentrated in urban areas. The lack of cooling disproportionately affects the poor, outdoor workers, and essential services like healthcare. While the Indian government has set energy efficiency standards for ACs, there is a critical need for policies that ensure universal access to cooling and protect vulnerable populations from extreme heat. Heat exposure caused approximately 489,000 deaths globally between 2000 and 2019.
- Cooling is essential for maintaining productivity and providing critical healthcare services like neonatal care.
- In India, 80% of the labor force works in heat-exposed sectors like agriculture and construction.
- Heat Action Plans (HAPs) have been developed but often face underfunding and weak implementation.
Indian adults consume 8 to 11 grams of salt daily, which is double the World Health Organization's (WHO) recommended limit of five grams. This high intake is a primary driver of hypertension, affecting 28.1% of adults, and significantly increases cardiovascular disease risks. The article emphasizes that most salt comes from home-made food and processed items (HFSS). It suggests a multi-pronged approach: public awareness, front-of-pack nutritional labeling, mandatory salt limits in processed foods, and integrating salt reduction into the National Multisectoral Action Plan (NMAP) for Non-Communicable Diseases (NCDs). Salt reduction is identified as a 'best buy' intervention for public health.
- Excessive salt intake is a major factor in the rising burden of non-communicable diseases (NCDs) like hypertension and cardiovascular issues in India.
- WHO recommends a daily salt intake of less than five grams, but Indians consume nearly double that amount.
- Hypertension affects approximately 28.1% of the Indian adult population, largely due to high sodium consumption.
India's Universal Immunisation Programme (UIP) is one of the world's largest, vaccinating millions of children and pregnant women annually. The article highlights the success of Mission Indradhanush (MI) and its intensified versions (IMI) in increasing full immunization coverage from 62% in 2014 to over 90%. Technological integrations like the U-WIN platform, building on the success of CO-WIN, have streamlined digital tracking and record-keeping. Despite challenges like vaccine hesitancy in remote areas, India has maintained its polio-free status since 2011 and achieved significant milestones in eliminating maternal and neonatal tetanus and Yaws. The 'Zero Measles-Rubella Elimination' campaign was launched in 2025.
- Mission Indradhanush was launched in 2014 to achieve 90% immunization coverage across India through targeted phases.
- The U-WIN platform enables nationwide, anytime-anywhere access to vaccination services and digital record-keeping for mothers and children.
- India has successfully eliminated Yaws (2016) and maternal and neonatal tetanus (2015) through sustained public health efforts.
Traditional medicine is practiced in 88% of WHO member states, serving as a primary healthcare source for billions. India's AYUSH sector has seen remarkable growth, with manufacturing revenue reaching ₹1.37 lakh crore. The establishment of the WHO Global Traditional Medicine Centre in India marks a significant milestone. Modern technologies like AI and big data are now being integrated into Ayurveda to enhance predictive care. As the world faces lifestyle diseases and climate change, traditional medicine offers sustainable, preventive health solutions. The theme for Ayurveda Day 2025 is 'Ayurveda for People & Planet.'
- Traditional medicine contributes to biodiversity conservation, nutrition security, and sustainable livelihoods.
- The AYUSH industry in India comprises over 92,000 micro, small, and medium enterprises.
- India has signed 25 bilateral agreements to promote traditional medicine globally.
Primary Health Centre (PHC) doctors are the backbone of India's rural healthcare, yet they face immense pressure from clinical loads and administrative tasks. A typical PHC doctor serves 20,000 to 50,000 people, managing everything from maternal health to infectious diseases. The introduction of multiple digital portals like IHIP and ABHA has inadvertently increased documentation work, leading to severe burnout. The Lancet and WHO have highlighted this global crisis. To achieve Universal Health Coverage and SDG 3, India must shift from a culture of compliance to one of facilitation, prioritizing the well-being of healthcare providers.
- PHC doctors manage over 100 outpatients daily plus emergency services and national health programs.
- Digital systems like IHIP and UWIN have created 'documentation duplication' instead of streamlining work.
- Burnout among PHC doctors is a systemic issue linked to poor staffing and excessive administrative reporting.
Kerala is witnessing a significant rise in Amoebic Meningoencephalitis (AME) cases, with 71 cases reported so far in 2024. While media attention often focuses on Naegleria fowleri (the 'brain-eating' amoeba), health officials clarify that nearly 99% of recent cases are caused by Acanthamoeba, a free-living amoeba widely found in water bodies and soil. Acanthamoeba primarily affects immunocompromised individuals but can also enter through skin wounds. Kerala's aggressive testing strategy, implemented after the 2023 Nipah outbreak, has led to earlier diagnosis and a reduction in mortality rates despite the surge in detected cases.
- AME is a rare but often fatal central nervous system infection caused by free-living amoebae (FLA).
- Acanthamoeba is ubiquitous in the environment, found in swimming pools, tap water, and even dust samples.
- Early diagnosis and intensive management have helped Kerala clinicians bring down the mortality rate of this high-fatality disease.
At the 2025 Global Conference on Climate and Health in Brazil, India’s welfare initiatives were highlighted as models for integrating climate and health goals. Programs like PM-POSHAN, Swachh Bharat, MNREGA, and PM Ujjwala Yojana (PMUY) demonstrate how non-health interventions can generate significant health and climate co-benefits. For instance, PMUY reduces indoor air pollution while cutting carbon emissions. The article advocates for a framework of institutionalized, health-anchored climate governance built on strategic prioritization, procedural integration (like health impact assessments), and participatory implementation using health as a mobilizing force for community engagement.
- The Belem Health Action Plan, to be launched at COP30, aims to define the global agenda on climate and health.
- India's PM-POSHAN scheme addresses malnutrition while building climate-resilient food systems through millet promotion.
- The Pradhan Mantri Ujjwala Yojana (PMUY) has successfully linked clean energy access to improved respiratory health and lower emissions.
India improved its rank to 99 out of 167 nations in the 2025 Sustainable Development Report, yet significant challenges remain in achieving SDG 3 (Good Health and Well-being). Key indicators like the Maternal Mortality Ratio (97 per 100,000) and Under-five Mortality Rate (32 per 1,000) still lag behind the 2030 targets. The article emphasizes a three-pronged approach: providing Universal Health Insurance, strengthening primary health centers, and integrating health education into school curricula. By focusing on preventive care and promoting healthy behaviors among the youth, India can reduce the burden of non-communicable diseases and improve overall life expectancy.
- SDG 3 aims to 'ensure healthy lives and promote well-being for all at all ages' by 2030.
- India's out-of-pocket health expenditure remains high at 13% of total consumption, exceeding the 7.83% target.
- Health education in schools is identified as a cost-effective measure to prevent diseases and improve long-term health outcomes.
A new study conducted in Nepal suggests that waning immunity against the Japanese Encephalitis Virus (JEV) can predispose individuals to more severe dengue fever. Both viruses belong to the genus Orthoflavivirus, and cross-reactivity between their antibodies can lead to antibody-dependent enhancement. This phenomenon occurs when low levels of JEV antibodies facilitate the entry of the dengue virus into cells, worsening the disease. The findings highlight the importance of timely JEV vaccine boosters, especially in regions like India where both diseases are prevalent, to protect against severe outcomes and manage the changing epidemiology of dengue.
- JEV and Dengue are both mosquito-borne diseases belonging to the same viral genus, Orthoflavivirus.
- Chymase, an enzyme released by mast cells, has been identified as a biomarker for severe dengue.
- Waning JEV immunity can lead to a 3x higher risk of developing severe dengue with warning signs.
National Health Account (NHA) estimates suggest a significant decline in India's Out-of-Pocket Expenditure (OOPE) from 64% in 2013-14 to 39% in 2021-22. While the government credits policy interventions for this trend, analysts argue the decline might be an artifact of data limitations in the NSS 75th round survey. Alternative data from the CMIE-CPHS suggests that OOPE as a share of household consumption is actually rising. The article calls for a more cautious interpretation of NHA data and the use of multiple survey bases to reflect the true financial burden on households facing skyrocketing medical prices.
- OOPE is the primary source of financing for healthcare in India, often leading to household poverty.
- NHA estimates are based on the NSS 75th round, which some experts find unrealistic compared to other surveys.
- Rising medical prices and hospital utilization rates suggest that healthcare is becoming more expensive, not less.
Prime Minister Narendra Modi laid the foundation stone for the PM Mega Integrated Textile Region and Apparel (PM MITRA) park in Dhar district, Madhya Pradesh. During the event, he urged citizens to embrace 'Swadeshi' by buying locally manufactured products to boost national development. He also launched the 'Swasth Nari Sashakt Parivar Abhiyaan' (SNSPA), a health initiative for women focusing on early disease detection and free check-ups. The PM MITRA scheme aims to strengthen India's textile sector through a '5F' vision: Farm to Fibre to Factory to Fashion to Foreign, enhancing both manufacturing and exports.
- The Dhar park is one of seven approved PM MITRA sites across India aimed at boosting the textile industry.
- The initiative follows a '5F' theme to integrate the entire textile value chain from farming to foreign exports.
- The SNSPA campaign provides free health screenings and medication for women until October 2.
The World Health Organization (WHO) has updated its Model Lists of Essential Medicines (EML) to include the GLP-1 class of drugs, such as semaglutide, for treating type 2 diabetes and obesity. This move is expected to lower costs and increase global access to these high-priced medications. The WHO Expert Committee reviewed evidence showing these drugs' effectiveness in glucose lowering and weight reduction. While currently expensive and largely unavailable in low- and middle-income countries, their inclusion in the EML encourages governments to prioritize their procurement and improve affordability for patients.
- GLP-1 (glucagon-like peptide-1) receptor agonists are now recognized as essential for managing type 2 diabetes and associated obesity.
- Inclusion in the WHO EML is a critical step toward making expensive, patented drugs more affordable through global procurement strategies.
- The move addresses the rising global burden of non-communicable diseases (NCDs), which account for a large share of out-of-pocket health spending.
Observed on September 17, World Patient Safety Day highlights the global challenge where one in ten patients experiences harm during hospitalisation. In India, the National Patient Safety Implementation Framework (2018-25) provides a roadmap for embedding safety into clinical programs. Key initiatives include the Pharmacovigilance Program of India and accreditation by the National Accreditation Board for Hospitals & Healthcare Providers (NABH). The article emphasizes the need for 'Patient Advisory Councils' to bring patient voices into decision-making and calls for a culture of safety across the entire healthcare ecosystem to prevent avoidable harm.
- World Patient Safety Day is observed annually on September 17 to promote global health safety and reduce patient harm.
- India's National Patient Safety Implementation Framework (2018-25) aims to integrate safety protocols into all levels of the health system.
- Less than 5% of hospitals in India have currently earned full NABH accreditation, highlighting a significant gap in safety standards.
In the landmark Sukdeb Saha vs The State of Andhra Pradesh case, the Supreme Court ruled that the right to mental health is an integral part of the right to life under Article 21 of the Constitution. The case arose from the suicide of a NEET candidate, highlighting the epidemic of student suicides in India. The court issued the 'Saha Guidelines,' requiring educational institutions to proactively develop support systems. This judgment shifts the perspective from viewing suicides as individual failures to recognizing them as outcomes of systemic neglect and 'structural violence,' mandating state responsibility for psychological well-being.
- The SC elevated mental health from a statutory right under the Mental Health Healthcare Act 2017 to a fundamental right under Article 21.
- The 'Saha Guidelines' mandate schools and colleges to establish mental health support systems and district-level monitoring committees.
- The ruling introduces the concept of 'structural violence' to describe how institutional neglect contributes to student suicides.